Merck discontinues Phase 3 trial for lung cancer combo drug Ruchika Sharma11 Aug 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the Phase 3 KeyVibe-008 trial based on...
Roche to halt lung cancer treatment trial Ruchika Sharma8 July 2024 5:43 PM ISTBased on these results, patients and investigators will be unblinded and we intend to halt the study.
CDSCO Panel Rejects Roche Products India local Phase III CT waiver proposal for Atezolizumab injection SC route Dr. Divya Colin18 Jun 2024 6:00 PM ISTNew Delhi: Recommending to conduct a phase III study in the Indian population to establish the safety and efficacy, the Subject Expert Committee (SEC)...
CDSCO Panel Approves Roche's Protocol Amendment Proposal For Anti-cancer Drug Atezolizumab, Lenvatinib, and Sorafenib Study Dr. Divya Colin14 April 2024 5:15 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Submit global regulatory status of Atezolizumab for IV, SC route: CDSCO Panel Tells Roche Products India Dr. Divya Colin12 April 2024 6:00 PM ISTNew Delhi: In response to the proposal presented by the drug major Roche Products India for granting permission to import and market Atezolizumab...
Merck concludes acquisition of Harpoon Therapeutics Ruchika Sharma13 March 2024 12:59 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has completed the acquisition of Harpoon Therapeutics, Inc. Harpoon is now a...
Roche's proposal for marketing Atezolizumab Injection for Subcutaneous route rejected by CDSCO Panel Dr. Divya Colin27 Jan 2024 6:00 PM ISTNew Delhi: Rejecting the drug major Roche's proposal to market the anti-cancer drug Atezolizumab Injection (1875mg/15ml vial) (Tecentriq) for a new...
Roche gets European Commission marketing nod for Tecentriq SC for multiple cancer types Ruchika Sharma20 Jan 2024 11:24 AM ISTBasel: Roche has announced that the European Commission has granted marketing authorisation for Tecentriq SC (atezolizumab), the European Union (EU)'s...
Roche subcutaneous injection of Tecentriq recommended by EU CHMP for multiple cancer types Ruchika Sharma19 Nov 2023 10:00 AM ISTBasel: Roche has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of...
Rznomics enters clinical trial collaboration with Roche to evaluate RZ-001 in combo with anti-PDL1 in liver cancer patients Ruchika Sharma15 Nov 2023 11:30 AM ISTSeongnam: Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, has...
Atezolizumab monotherapy bests single-agent chemotherapy among patients with advanced non-small-cell lung cancer Dr. Shravani Dali5 Sept 2023 8:00 PM ISTAtezolizumab monotherapy bests single-agent chemotherapy among patients with advanced non-small-cell lung cancer suggests a new study published in...
Roche Tecentriq SC approved in Great Britain Ruchika Sharma2 Sept 2023 10:00 AM ISTInjecting Tecentriq subcutaneously (under the skin) takes approximately seven minutes.
